Outlook for 2024 Non-GAAP Results
$ billions, except EPS or as noted | November 2024 Outlook | July 2024 Outlook | February 2024 Outlook |
Revenues* | $16.1 - $16.5 | $16.0 - $16.4 | $15.7 - $16.3 |
AUSTEDO ($m)* | ~1,600 | ~1,600 | ~1,500 |
AJOVY ($m)* | ~500 | ~500 | ~500 |
UZEDY ($m)* | ~100 | ~80 | ~80 |
COPAXONE ($m)* | ~500 | ~450 | ~400 |
Operating Income | 4.2 - 4.5 | 4.1 - 4.5 | 4.0 - 4.5 |
Adjusted EBITDA | 4.7 - 5.0 | 4.6 - 5.0 | 4.5 - 5.0 |
Finance Expenses ($m) | ~1,000 | ~1,000 | ~1,000 |
Tax Rate | 14% - 17% | 14% - 17% | 14% - 17% |
Diluted EPS ($) | 2.40 - 2.50 | 2.30 - 2.50 | 2.20 - 2.50 |
Free Cash Flow** | 1.7 - 2.0 | 1.7 - 2.0 | 1.7 - 2.0 |
CAPEX* | ~0.5 | ~0.5 | ~0.5 |
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。